BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Front Oncol 2021;11:641428. [PMID: 34268109 DOI: 10.3389/fonc.2021.641428] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
Number Citing Articles
1 Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol 2022;12:958720. [DOI: 10.3389/fonc.2022.958720] [Reference Citation Analysis]
2 Ephraim R, Fraser S, Nurgali K, Apostolopoulos V. Checkpoint Markers and Tumor Microenvironment: What Do We Know? Cancers 2022;14:3788. [DOI: 10.3390/cancers14153788] [Reference Citation Analysis]
3 Ding K, Zheng Z, Han Y, Huang X. Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. Cell Cycle 2022;:1-17. [PMID: 35894701 DOI: 10.1080/15384101.2022.2103898] [Reference Citation Analysis]
4 Aghamajidi A, Maleki Vareki S. The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer. Cancers 2022;14:3563. [DOI: 10.3390/cancers14153563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhang Y, Zhang X, Kuang M, Yu J. Emerging insights on immunotherapy in liver cancer. Antioxid Redox Signal 2022. [PMID: 35754339 DOI: 10.1089/ars.2022.0047] [Reference Citation Analysis]
6 Zhu L, Meng D, Wang X, Chen X. Ferroptosis-Driven Nanotherapeutics to Reverse Drug Resistance in Tumor Microenvironment. ACS Appl Bio Mater 2022. [PMID: 35614872 DOI: 10.1021/acsabm.2c00199] [Reference Citation Analysis]
7 González-ochoa S, Tellez-bañuelos MC, Méndez-clemente AS, Bravo-cuellar A, Hernández Flores G, Palafox-mariscal LA, Haramati J, Pedraza-brindis EJ, Sánchez-reyes K, Ortiz-lazareno PC, Wang S. Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells. Journal of Immunology Research 2022;2022:1-19. [DOI: 10.1155/2022/1810804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Andrea AE, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. Front Immunol 2022;13:830292. [PMID: 35211124 DOI: 10.3389/fimmu.2022.830292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ushio R, Murakami S, Saito H. Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. JCM 2022;11:1855. [DOI: 10.3390/jcm11071855] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
10 Kaushik I, Ramachandran S, Zabel C, Gaikwad S, Srivastava SK. The evolutionary legacy of immune checkpoint inhibitors. Semin Cancer Biol 2022:S1044-579X(22)00076-1. [PMID: 35341912 DOI: 10.1016/j.semcancer.2022.03.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
11 Zhang X, Li H, Lv X, Hu L, Li W, Zi M, He Y. Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors. Life 2022;12:409. [DOI: 10.3390/life12030409] [Reference Citation Analysis]
12 Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther 2022. [PMID: 35130816 DOI: 10.1080/14712598.2022.2038132] [Reference Citation Analysis]
13 Reed T, Schorey J, D'Souza-Schorey C. Tumor-Derived Extracellular Vesicles: A Means of Co-opting Macrophage Polarization in the Tumor Microenvironment. Front Cell Dev Biol 2021;9:746432. [PMID: 34692700 DOI: 10.3389/fcell.2021.746432] [Cited by in F6Publishing: 1] [Reference Citation Analysis]